（文章来源：每日经济新闻） 艾德生物（300685.SZ）12月8日在投资者互动平台表示，公司基于NGS 10基因产品开展的非小细胞肺 癌驱动基因阳性患者的多中心真实世界MRD研究，已于12月6日在ESMO-Asia会议上进行口头报告。在 研产品的获批情况请以公司公告为准。 每经AI快讯，有投资者在投资者互动平台提问：请问公司有哪些MRD产品和在研项目？ ...

Financial Performance - In the first three quarters of 2025, the company achieved revenue of 866 million RMB, a year-on-year increase of 2.08% [2] - Net profit attributable to shareholders reached 263 million RMB, up 15.50% year-on-year, with a non-recurring net profit growth of 18.05% [2] - The net profit for 2025 has already surpassed the total for the entire year of 2024, indicating a robust growth trend [2] Sales Structure Adjustments - The domestic sales structure was adjusted in Q4 2024, leading to improved growth in 2025, with a reduction in related expense ratios [2] - International sales structure adjustments were made in the first half of 2025, focusing on key markets and optimizing the distributor system [3] Quarterly Performance Insights - In Q3 2025, net profit decreased by 11.92% due to a provision for bad debts amounting to 18.18 million RMB related to a long-term receivable from a technology transfer [4] - Revenue in Q3 declined by 6.12%, primarily due to changes in VAT rates and a decrease in income from clinical research services [4] Expense Management - Sales expenses increased in Q3 due to higher marketing and personnel costs, but the overall trend shows a decrease in sales expense ratio over recent years [6] - R&D expenses fluctuated between 15% and 18%, while management expenses remained stable at around 7% to 8% [6] Market Expansion - The company has strategically entered Southeast Asian markets, focusing on countries like Singapore, Vietnam, Malaysia, and Indonesia, which are expected to drive future growth [9] - The Southeast Asian market is seen as a significant growth point for international business, despite its current smaller revenue base [9] Product Development and Collaborations - New products in the registration process include HRD products and PCR tests, with data to be disclosed at the upcoming ESMO-Asia conference [10] - Collaboration with Sailu Medical aims to enhance the company's competitive edge in the NGS market by integrating core technologies [11] Regulatory and Market Access - Currently, the company's products are not included in national health insurance, but tumor gene testing has been incorporated into local insurance schemes, enhancing market penetration [12] - The company is preparing for potential participation in the upcoming round of centralized procurement in Jiangsu Province [12] Share Buyback Plan - The board plans to use 100 to 200 million RMB for share repurchase, pending shareholder approval [5]